LUNG
USDPulmonx Corporation Common Stock
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$1.790
Máximo
$1.790
Mínimo
$1.660
Volumen
0.89M
Fundamentos de la Empresa
Capitalización de Mercado
69.4M
Industria
Dispositivos médicos
País
United States
Estadísticas de Negociación
Volumen Promedio
2.37M
Bolsa
NMS
Moneda
USD
Rango de 52 Semanas
Informe de Análisis de IA
Última actualización: 31 oct 2025LUNG (Pulmonx Corporation) Market Analysis: Undervalued MedTech with Mixed Signals
Quick Overview
Pulmonx (LUNG) trades at $2.03 as of October 31, 2025, with a negative P/E ratio (-1.27) and small market cap ($82.6M). Recent analyst upgrades and a management shakeup dominate headlines, while technical indicators show caution. Fundamental scores suggest potential value, but debt and weak equity returns weigh down long-term confidence.
Key News Sentiment
- Analyst Optimism Amid Lower Targets
- Lake Street and D. Boral Capital kept "Buy" ratings but slashed price targets (from $8 → $4 and $16 → $14).
- Why it matters: Analysts see long
Noticias Relacionadas
Lake Street Maintains Buy on Pulmonx, Lowers Price Target to $4
Lake Street analyst Frank Takkinen maintains Pulmonx with a Buy and lowers the price target from $8 to $4.
D. Boral Capital Maintains Buy on Pulmonx, Lowers Price Target to $14
D. Boral Capital analyst Jason Kolbert maintains Pulmonx with a Buy and lowers the price target from $16 to $14.
Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025
Glen French, member of the Board of Directors and former Pulmonx President and Chief Executive Officer, reappointed President and Chief Executive OfficerDerrick Sung, former Pulmonx Chief Financial Officer, appointed
Predicción de IABeta
Recomendación de IA
Actualizado el: 4 nov 2025, 18:55
61.4% Confianza
Riesgo y Negociación
Punto de Entrada
$1.81
Toma de Ganancias
$2.06
Stop Loss
$1.66
Factores Clave
Acciones Relacionadas
INBKZ
First Internet Bancorp 6.0% Fixed-to-Floating Rate Subordinated Notes Due 2029
KTOS
Kratos Defense & Security Solutions Inc.
IPA
ImmunoPrecise Antibodies Ltd.
KRT
Karat Packaging Inc.
LVTX
LAVA Therapeutics N.V. Ordinary Shares
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.